格列齐特结合舒洛地特治疗对糖尿病肾病患者血管内皮细胞生长因子的影响

EFFECT OF GLICLAZIDE COMBINED WITH SULODEXIDE ON VEGF IN THE TREATMENT OF PATIENTS WITH DIABETIC NEPHROPATHY

目的研究格列齐特结合舒洛地特治疗对糖尿病肾病患者血管内皮细胞生长因子的影响。方法随机选取2012年4月—2013年6月我院收治的糖尿病肾病患者120例,将其随机分为对照组和观察组各60例,对照组给予舒洛地特治疗,观察组在此基础上同时服用格列齐特,于治疗后第四周、第八周,测定患者体内血管内皮细胞生长因子(VEGF)。结果使用格列齐特结合舒洛地特治疗后,患者体内VEGF水平显著下降(tc=11.051,td=17.176,P<0.05)。结论格列齐特结合舒洛地特治疗可有效降低患者体内血管内皮细胞生长因子的表达。

Objective To study the treatment effect of Gliclazide in combination with Sulodexide on endo- thelial cell growth factor in diabetic vascular nephropathy patients. Methods A total of 120 patients with diabetic nephropathy were randomly divided into control group and observation group with 60 cases in each group, the control group was given Sulodexide treatment, the observation group on the basis of taking Gli- clazide, in fourth weeks, eighth weeks after treatment, patients with vascular endothelial cells determina- tion of the in vivo growth factor （VEGF）. Results The use of Gliclazide special treated with combination of Sulodexide, the level of VEGF in patients was significantly decreased （tc = 11. 051, td = 17. 176, P 均〈 0.05）. Conclusion Gliclazide in combination with Sulodexide therapy can effectively reduce the expression of vascular endothelial cells of patients with body growth factor.